secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001193125-24-169713
Event type: m_and_a
Sentiment:  positive
Materiality: 0.68
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront
--------------------------------------------------------------------------------

- Upfront payment $35M plus regulatory milestone payments and royalties.
- Pair includes 177Lu-DOTA-RM2 (therapeutic) and 68Ga-DOTA-RM2 (diagnostic) targeting GRPR in prostate, breast, and other cancers.
- Lantheus plans Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer in 2025; 68Ga-DOTA-RM2 as companion diagnostic.
- Strengthens Lantheus' prostate cancer portfolio and expands pipeline to include breast cancer.
- Life Molecular will complete ongoing Phase 1/2a dose escalation study in collaboration with Lantheus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/0001193125-24-169713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524169713/d651116d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-169713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer